METTL21A

Across TCGA pan-cancer cohorts, METTL21A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated METTL21A data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher METTL21A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated METTL21A expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, PDAC, and GBM are the cancer types where METTL21A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	1.000	0.620	.011	12	view →
PDAC	DFS	Quartile	III,IV	0.095	0.582	.026	6	view →
GBM	DFS	Quartile	All	0.953	0.542	.026	3	view →
LSCC	DFS	Tertile	II,III,IV	0.763	0.490	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

METTL21A–UCEC (OS)

Open the UCEC breakdown →